Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Conditions
Brief summary
The study will test the tolerability and efficacy of the combination therapy Imatinib/Hydroxyurea (HU) in patients with chronic myeloid leukemia (CML) in first chronic phase (CP1) newly diagnosted or failing interferon-based therapy.
Detailed description
The protocol consists of a part 1, a phase I study that will enrol 20 patients, with the goal to determine the safety of the combination as well as the maximal tolerated dose. If the toxicity of the combination is acceptable, up to 200 more patients may be recruited and randomized to receive either Imatinib/HU or Imatinib alone (part 2). Patients who meet the inclusion criteria will be started on 400 mg Imatinib daily. In part 1 of the protocol, the dose of HU will be increased by 500 mg at 3-weekly intervals until the maximal tolerated dose has been reached. In part 2 of the study, patients will be randomized to receive either the combination or Imatinib monotherapy. Hematological and cytogenetic response will be evaluated at 3-months intervals during the first year, and at 6 months' intervals thereafter. Primary endpoints for part 1 are dose-limiting toxicity and maximal tolerated dose. Primary endpoints for part 2 are the rates of major and complete molecular response at 6, 12 and 18 months, respectively.
Interventions
DRUGImatinib
DRUGHydroxyurea
Sponsors
University of Leipzig
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Ph-positive CML in CP1, newly diagnosed or resistant (hematologic or cytogenetic) or intolerant to interferon-based therapy 2. Age ≥ 18 years 3. Negative pregnancy test 4. Low- and intermediate risk patients younger than 45 with an HLA (Human Leukocyte Antigen) -matched sibling donor and medically fit to undergo allografting should be included only after they have been adequately counselled about the potential risk (of disease progression) associated with delaying the allograft 5. Informed consent
Exclusion criteria
1. Objective signs of disease progression beyond CP1 defined as * bone marrow or peripheral blood blasts \> 15% and/or * blasts + promyelocytes ≥ 30% and/or * peripheral blood basophils ≥ 20% and/or * platelets \< 100/nl and/or * chromosomal abnormalities in addition to the Ph chromosome 2. Findings suggestive of extramedullary involvement 3. Any severe and uncontrolled medical condition 4. Previous treatment with Imatinib (only part 2 of the study) 5. History of non-compliance 6. Simultaneous inclusion in other studies Important note: previous treatment with Imatinib only is not an exclusion criterion for part 1 of the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| number of participants with complete molecular response as a measure of efficacy | 18 months | complete molecular response is achieved if BCR-ABL (breakpoint cluster region-Abelson murine leukemia) transcripts became undetectable |
Outcome results
None listed